BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

...with programs in Phase I and Phase II testing. Merck obtained molecules targeting ATR and DNA-PK...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS). BMS also inherited CC-115, a dual mTOR and DNA-PK...
...CCNE1 (CCNE) - Cyclin E1 mTOR (FRAP; RAFT1) - Mammalian target of rapamycin DNA-PK - DNA-dependent protein kinase...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...Impact has internal programs in discovery against other DDR targets including ATR, ATM, Chk1 and DNA-PK...
...BRCA1 - Breast cancer 1 early onset Chk1 (CHEK1) - Checkpoint kinase 1 DNA-PK - DNA-dependent protein kinase...
...related (ATR) (FRP1) Ataxia telangiectasia mutated (ATM) Breast cancer 1 early onset (BRCA1) Checkpoint kinase 1 (Chk1) (CHEK1) DNA-dependent protein kinase (DNA-PK) Poly(ADP-ribose...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...patient-derived xenograft models. The company is investigating two ATR inhibitors, an ATM inhibitor and a DNA-PK...
...1 Chk2 (CHEK2) - Checkpoint kinase 2 CDK12 - Cyclin dependent kinase 12 DNA-PK - DNA-dependent protein kinase...
BioCentury | Jan 25, 2019
Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

...pathway. Merck announced Jan. 24 that it granted Vertex rights two DDR inhibitors targeting DNA-dependent protein kinase (DNA-PK...
...Germany Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Gene/Cell therapy Lauren Martz M9831, VX-984 Merck KGaA Vertex Pharmaceuticals Inc. DNA-dependent protein kinase (DNA-PK) CRISPR DNA...
BioCentury | Jan 24, 2019
Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

...repair pathway. Merck announced Thursday that it granted Vertex rights two DDR inhibitors targeting DNA-dependent protein kinase (DNA-PK...
...programs in other indications. Vertex lost $3.31 to $186.58 on Thursday. Lauren Martz Merck KGaA Vertex Pharmaceuticals Inc. DNA-dependent protein kinase (DNA-PK...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...INDICATION: Colorectal cancer, pancreatic cancer Patient sample and mouse studies suggest combining DNA-PK inhibitors with the...
...could include testing the combination in additional models of colorectal and pancreatic cancers. TARGET/MARKER/PATHWAY: DNA-dependent protein kinase (DNA-PK...
...email: ygm@mail.sysu.edu.cn CONTACT: Haipeng Zhang, Jinan University, Guangzhou, China email: haipeng23@163.com Alicia Parker Jinan University Sun Yat-sen University DNA-dependent protein kinase (DNA-PK) Pancreatic...
BioCentury | Jun 20, 2018
Distillery Techniques

Drug platforms

...inhibitor, and an inhibitor of the replication protein A1 (RPA1)-p53 interaction -- and a DNA-dependent protein kinase (DNA-PK...
BioCentury | Jun 15, 2017
Clinical News

Merck reports Phase Ia data for DNA-PK inhibitor M3814 in solid tumors

...ORR), tumor size, progression-free survival (PFS), overall survival (OS) and pharmacokinetics. M3814 is a DNA-dependent protein kinase (DNA-PK...
...Xetra:MRK), Darmstadt, Germany Product: M3814 , MSC 2490484A Business: Cancer Molecular target: DNA-dependent protein kinase (DNA-PK) Description: DNA-PK...
...and pharmacokinetics Status: Phase Ia/Ib data Milestone: NA Julian Zhu M3814 MSC 2490484A American Society of Clinical Oncology Merck KGaA DNA-dependent protein kinase (DNA-PK) ASCO...
BioCentury | Jun 15, 2017
Clinical News

Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors

...response rate (ORR), clinical benefit rate (CBR) and progression-free survival (PFS). M3814 is a DNA-dependent protein kinase (DNA-PK...
...Xetra:MRK), Darmstadt, Germany Product: M3814 , MSC 2490484A Business: Cancer Molecular target: DNA-dependent protein kinase (DNA-PK) Description: DNA-PK...
...survival (PFS) Status: Phase I data Milestone: NA Julian Zhu M3814 MSC 2490484A American Society of Clinical Oncology Merck KGaA DNA-dependent protein kinase (DNA-PK) ASCO...
Items per page:
1 - 10 of 18